Studies so far suggest CagriSema outperforms semaglutide alone for weight loss. In a phase 2 trial with people who have type 2 diabetes, CagriSema (both components at 2.4 mg) led to a 15.6% reduction in body weight after 32 weeks, compared to 5.1% with semaglutide alone at the same dose. For blood sugar control, CagriSema reduced HbA1c by 2.2%, while semaglutide alone managed 1.8%—a noticeable improvement, though not dramatically different.
More recently, a phase 3 trial (REDEFINE 1) in people with obesity or overweight showed CagriSema achieving a 22.7% weight loss after 68 weeks, compared to 16.1% with semaglutide alone. This suggests CagriSema could offer a bigger bang for weight loss.
